Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
17 11 2021
Historique:
received: 25 03 2020
revised: 21 02 2021
accepted: 31 03 2021
pubmed: 21 4 2021
medline: 11 3 2022
entrez: 20 4 2021
Statut: ppublish

Résumé

All WHO regions have set measles elimination objective for 2020. To address the specific needs of achieving measles elimination, Nigeria is using a strategy focusing on improving vaccination coverage with the first routine dose of (monovalent) measles (MCV1) at 9 months, providing measles vaccine through supplemental immunization activities (children 9-59 months), and intensified measles case-based surveillance system. We reviewed measles immunization coverage from population-based surveys conducted in 2010, 2013 and 2017-18. Additionally, we analyzed measles case-based surveillance reports from 2008-2018 to determine annual, regional and age-specific incidence rates. Survey results indicated low MCV1 coverage (54.0% in 2018); with lower coverage in the North (mean 45.5%). Of the 153,097 confirmed cases reported over the studied period, 85.5% (130,871) were from the North. Moreover, 70.8% (108,310) of the confirmed cases were unvaccinated. Annual measles incidence varied from a high of 320.39 per 1,000,000 population in 2013 to a low of 9.80 per 1,000,000 in 2009. The incidence rate is higher among the 9-11 months (524.0 per million) and 12-59 months (376.0 per million). Between 2008 and 2018, the incidence rate had showed geographical variation, with higher incidence in the North (70.6 per million) compare to the South (17.8 per million). The aim of this study was to provide a descriptive analysis of measles vaccine coverage and incidence in Nigeria from 2008 to 2018 to assess country progress towards measles elimination. Although the total numbers of confirmed measles cases had decreased over the time period, measles routine coverage remains sub-optimal, and the incidence rates are critically high. The high burden of measles in the North highlight the need for region-specific interventions. The measles program relies heavily on polio resources. As the polio program winds down, strong commitments will be required to achieve elimination goals.

Identifiants

pubmed: 33875267
pii: S0264-410X(21)00424-2
doi: 10.1016/j.vaccine.2021.03.095
pii:
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

C89-C95

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anne Eudes Jean Baptiste (AE)

World Health Organization, Country Office, Abuja, Nigeria. Electronic address: jeana@who.int.

Balcha Masresha (B)

World Health Organization, African Regional Office, Brazzaville, Congo.

John Wagai (J)

World Health Organization, Country Office, Abuja, Nigeria.

Richard Luce (R)

World Health Organization, Inter-country Support Team for West Africa, Ouagadougou, Burkina Faso.

Joseph Oteri (J)

National Primary Health Care Development Agency, Abuja, Nigeria.

Boubacar Dieng (B)

Technical Assistance Consultant, Global Alliance for Vaccines and Immunizations, Nigeria.

Samuel Bawa (S)

World Health Organization, Country Office, Abuja, Nigeria.

Obianuju Caroline Ikeonu (OC)

World Health Organization, Country Office, Abuja, Nigeria.

Martin Chukwuji (M)

World Health Organization, Country Office, Abuja, Nigeria.

Fiona Braka (F)

World Health Organization, Country Office, Abuja, Nigeria.

E A M Sanders (EAM)

Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands.

Susan Hahné (S)

Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands.

Eelko Hak (E)

Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH